Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | Aug 19, 2014 | 1 comment


Dr. Sean Ekins is Principal Investigator of GRIN, which is now in its second year. Dr. Ekins is a clinical pharmacologist by training with over 18 years of experience in pre-clinical drug development, toxicity and computational drug discovery research in large Pharma (Lilly, Pfizer), biotech, informatics software companies (GeneGo, Collaborative Drug Discovery, Inc.) and start up drug companies (Phoenix Nest).

As Chief Science Officer of HNF, it is his responsibility to oversee the success of our TRIAD research program in which we fund translational research (pre-clinical and clinical),  projects. HNF’s goal is to expedite the research process from bench to bedside. While there has been a considerable amount of research on CMT there is urgency to provide the thousands of patients progressing rapidly, with a therapeutic that offers a benefit to them.

As we continue to translate our research and partner with various academics, industry leaders, government and not-for-profit stakeholders that are aligned with HNF’s mission, your participation is an intricate and an important part of the process. Please Join us and contribute to GRIN, our patient registry, which will help us in our quest to cure CMT.

Learn more on this topic

Related Blog Posts

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

In Memoriam

The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment

1 Comment

  1. J Brian C Saunders

    Could you please give me a definition of CMT type 2 axonal
    Thanking you in anticipation



Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news